Telomerase reverse transcriptase promoter mutations in hepatocellular carcinogenesis

Abstract

Through several studies exploiting next-generation sequencing, we are obtaining a clearer picture of the complex genetic and molecular landscape of hepatocellular carcinoma (HCC). Consistent with the findings of other cancer types, telomerase reverse transcriptase (TERT) promoter mutations have been frequently reported in HCC. C228T and C250T are two major types of hot spot mutations in the TERT promoter region. Besides, in hepatitis B virus (HBV)-related HCC cases, the TERT promoter is recurrently interrupted by integration of HBV DNA. TERT promoter mutations are thought to be an early event in HCC carcinogenesis, and they are significantly associated with disease progression. In this review, we provide an updated overview of the somatic mutations in the TERT promoter region and discuss their possible roles in the development of HCC.

Keywords

Hepatocellular carcinoma / telomerase reverse transcriptase / mutation / hepatitis B virus

References

[1] Pezzuto F,Buonaguro FM.Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma..Infect Agent Cancer2017;12:27 PMCID:PMC5437489

[2] Torre LA,Siegel RL,Lortet-Tieulent J.Global cancer statistics, 2012..CA Cancer J Clin2015;65:87-108

[3] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[4] Kudo M.Systemic therapy for hepatocellular carcinoma: latest advances..Cancers (Basel)2018;10: PMCID:PMC6266463

[5] Ringelhan M,O’Connor T,Heikenwalder M.The immunology of hepatocellular carcinoma..Nat Immunol2018;19:222-32

[6] Zucman-Rossi J,Nault JC.Genetic landscape and biomarkers of hepatocellular carcinoma..Gastroenterology2015;149:1226-39.e4

[7] Kawai-Kitahata F,Tanaka S,Murakawa M.Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features..J Gastroenterol2016;51:473-86

[8] Totoki Y,Covington KR,Creighton CJ.Trans-ancestry mutational landscape of hepatocellular carcinoma genomes..Nat Genet2014;46:1267-73

[9] Liu L,Andrews LG.Genetic and epigenetic modulation of telomerase activity in development and disease..Gene2004;340:1-10

[10] Lendvay TS,Sah J,Lundblad V.Senescence mutants of Saccharomyces cerevisiae with a defect in telomere replication identify three additional EST genes..Genetics1996;144:1399-412 PMCID:PMC1207693

[11] Lingner J.Purification of telomerase from Euplotes aediculatus: requirement of a primer 3’ overhang..Proc Natl Acad Sci U S A1996;93:10712-7 PMCID:PMC38220

[12] Cukusic A,Sopta M.Telomerase regulation at the crossroads of cell fate..Cytogenet Genome Res2008;122:263-72

[13] Pestana A,Sobrinho-Simoes M.TERT biology and function in cancer: beyond immortalisation..J Mol Endocrinol2017;58:R129-R46

[14] Low KC.Telomerase: central regulator of all of the hallmarks of cancer..Trends Biochem Sci2013;38:426-34

[15] Liu T,Xu D.Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: biological and clinical implications..Genes (Basel)2016;7:E38 PMCID:PMC4962008

[16] Daniel M,Tollefsbol TO.Regulation of the human catalytic subunit of telomerase (hTERT)..Gene2012;498:135-46 PMCID:PMC3312932

[17] Poole JC,Tollefsbol TO.Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT)..Gene2001;269:1-12

[18] Greenberg RA,Deng H,Hann SR.Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation..Oncogene1999;18:1219-26

[19] Oh S,Yim J.Identification of Mad as a repressor of the human telomerase (hTERT) gene..Oncogene2000;19:1485-90

[20] Cerezo A,Schuermann M,Boukamp P.Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT..J Cell Sci2002;115:1305-12

[21] Dwyer JM.Ets2 transcription factor, telomerase activity and breast cancer..Clin Exp Pharmacol Physiol2010;37:83-7

[22] Wu KJ,Amacker M,Polack A.Direct activation of TERT transcription by c-MYC..Nat Genet1999;21:220-4

[23] Kanaya T,Hamada K,Kitagawa Y.Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription..Clin Cancer Res2000;6:1239-47

[24] Akincilar SC,Boon PL,Fullwood MJ.Long-range chromatin interactions drive mutant TERT promoter activation..Cancer Discov2016;6:1276-91

[25] Barthel FP,Tang M,Hu X.Systematic analysis of telomere length and somatic alterations in 31 cancer types..Nat Genet2017;49:349-57 PMCID:PMC5571729

[26] Huang FW,Xu MJ,Chin L.Highly recurrent TERT promoter mutations in human melanoma..Science2013;339:957-9 PMCID:PMC4423787

[27] Alexiadis M,Chu S,Stewart CJR.Mutational landscape of ovarian adult granulosa cell tumors from whole exome and targeted TERT promoter sequencing..Mol Cancer Res2019;17:177-85

[28] Killela PJ,Jiao Y,Agrawal N.TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal..Proc Natl Acad Sci U S A2013;110:6021-6 PMCID:PMC3625331

[29] Koelsche C,Capper D,Sturm D.Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system..Acta Neuropathol2013;126:907-15

[30] Allory Y,Sagrera A,Marques M.Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome..Eur Urol2014;65:360-6

[31] Borah S,Zaug AJ,Dancik GM.Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer..Science2015;347:1006-10 PMCID:PMC4640672

[32] Heidenreich B,Rachakonda PS,Requena C.Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma..Nat Commun2014;5:3401

[33] Horn S,Rachakonda PS,Sucker A.TERT promoter mutations in familial and sporadic melanoma..Science2013;339:959-61

[34] Hurst CD,Knowles MA.Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine..Eur Urol2014;65:367-9

[35] Remke M,Peacock J,Koelsche C.TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma..Acta Neuropathol2013;126:917-29 PMCID:PMC3830749

[36] Vinagre J,Populo H,Lyra J.Frequency of TERT promoter mutations in human cancers..Nat Commun2013;4:2185

[37] Wu S,Li C,Li X.Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study..Eur Urol2014;65:274-7

[38] Campos MA,Fernandes M,Pardal J.TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma..J Am Acad Dermatol2019;80:660-9.e6

[39] Lee HW,Jang SY,Park WJ.Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma..Medicine (Baltimore)2017;96:e5766 PMCID:PMC5293416

[40] Cevik D,Ozturk M.Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations..World J Gastroenterol2015;21:311-7 PMCID:PMC4284350

[41] Lee SE,Kim WY,Kim WS.Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma..Oncotarget2016;7:69267-75 PMCID:PMC5342476

[42] Nault JC,Pilati C,Bioulac-Sage P.High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions..Nat Commun2013;4:2218 PMCID:PMC3731665

[43] Huang W,Li C,Shang YK.Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma..Oncotarget2017;8:26288-97 PMCID:PMC5432257

[44] Yang XJ,Chen Y,Ma Y.Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma..Oncotarget2016;7:27838-47 PMCID:PMC5053691

[45] Chen YL,Chang CN,Hsu HC.TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection..Int J Surg2014;12:659-65

[46] Yuan XT,Yu JY,Sun C.The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma..Oncotarget2017;8:23120-9 PMCID:PMC5410290

[47] Pezzuto F,Buonaguro L,Tatangelo F.Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma..Oncotarget2016;7:54253-62 PMCID:PMC5342339

[48] Cancer Genome Atlas Research NetworkElectronic address: [e-mail]; Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma..Cell2017;169:1327-41.e23 PMCID:PMC5680778

[49] Nishida N,Kaido T,Yamao K.Molecular scoring of hepatocellular carcinoma for predicting metastatic recurrence and requirements of systemic chemotherapy..Cancers (Basel)2018;10:E367 PMCID:PMC6210853

[50] Eichenmuller M,Kreuder M,Schwarzmayr T.The genomic landscape of hepatoblastoma and their progenies with HCC-like features..J Hepatol2014;61:1312-20

[51] Fujimoto A,Totoki Y,Kato M.Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer..Nat Genet2016;48:500

[52] Nault JC,Di Tommaso L,Zafrani ES.Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis..Hepatology2014;60:1983-92

[53] Calderaro J,Imbeaud S,Letouze E.Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification..J Hepatol2017;67:727-38

[54] Donati B,Pingitore P,Caddeo A.Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease..Cancer Med2017;6:1930-40 PMCID:PMC5548883

[55] Dongiovanni P,Valenti L.Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors..World J Gastroenterol2014;20:12945-55 PMCID:PMC4177475

[56] Ki Kim S,Hatano E,Takeda H.TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma..Int J Cancer2016;139:2512-8

[57] Jiao J,Stevenson HL,Fisher-Hoch SP.Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: prevalence and risk factors..Hepatol Commun2018;2:718-31 PMCID:PMC5983165

[58] Jiang Z,Liu J,Kennemer MI.The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients..Genome Res2012;22:593-601 PMCID:PMC3317142

[59] Khoury JD,Williams MD,Yao H.Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq..J Virol2013;87:8916-26 PMCID:PMC3754044

[60] Paterlini-Brechot P,Murakami Y,Gozuacik D.Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene..Oncogene2003;22:3911-6

[61] Tornesello ML,Izzo F.Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections..Oncotarget2016;7:25087-102 PMCID:PMC5041890

[62] Kaslow DC,Bloom DE,Salisbury D.Vaccine candidates for poor nations are going to waste..Nature2018;564:337-9

[63] Yang X,Lin J,Wan X.Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue..Int J Cancer2017;140:1324-30

[64] Ferber MJ,Yu C,McGee A.Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers..Oncogene2003;22:3813-20

[65] Sung WK,Li S,Liu X.Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma..Nat Genet2012;44:765-9

[66] Gozuacik D,Saigo K,Mugnier C.Identification of human cancer-related genes by naturally occurring hepatitis B virus DNA tagging..Oncogene2001;20:6233-40

[67] Ding D,Hua D,Li L.Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach..PLoS Genet2012;8:e1003065 PMCID:PMC3516541

[68] Fujimoto A,Abe T,Hosoda F.Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators..Nat Genet2012;44:760-4

[69] Li W,Lee NP,Chen S.HIVID: an efficient method to detect HBV integration using low coverage sequencing..Genomics2013;102:338-44

[70] Toh ST,Liu LZ,Babrzadeh F.Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations..Carcinogenesis2013;34:787-98

[71] Lau CC,Ching AK,Li JW.Viral-human chimeric transcript predisposes risk to liver cancer development and progression..Cancer Cell2014;25:335-49

[72] Saitta C,Barbera A,Smedile A.Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma..Liver Int2015;35:2311-7

[73] Yan H,Zhang L,Wang Y.Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma..Hepatology2015;61:1821-31

[74] Chiu YT,Choi SW,Ho DW.Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma..J Hepatol2016;64:1256-64

[75] Zhao LH,Yan HX,Zeng X.Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma..Nat Commun2016;7:12992 PMCID:PMC5059470

[76] Lee WY,Choo CCS.Comprehensive review of hepatitis B virus-associated hepatocellular carcinoma research through text mining and big data analytics..Biol Rev Camb Philos Soc2018;

[77] Schulze K,Letouze E,Calderaro J.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets..Nat Genet2015;47:505-11 PMCID:PMC4587544

[78] Iliopoulos D,Drakaki A,Tsezou A.Epigenetic regulation of hTERT promoter in hepatocellular carcinomas..Int J Oncol2009;34:391-9

[79] Kumakura S,Yagisawa J,Tsutsui T.Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells..Cancer Res2005;65:2778-86

[80] Widschwendter A,Hubalek MM,Fiegl H.Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer..Gynecol Oncol2004;93:407-16

[81] Guilleret I.Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres..Exp Cell Res2003;289:326-34

[82] Guilleret I,Grange F,Bosman FT.Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity..Int J Cancer2002;101:335-41

[83] Dessain SK,Reddel RR,Weinberg RA.Methylation of the human telomerase gene CpG island..Cancer Res2000;60:537-41

[84] Zhang H,Ye J,Zhou D.Promoter hypermethylation of TERT is associated with hepatocellular carcinoma in the Han Chinese population..Clin Res Hepatol Gastroenterol2015;39:600-9

[85] Li Y,Sun W,Cheng HS.Non-canonical NF-kappaB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation..Nat Cell Biol2015;17:1327-38 PMCID:PMC4772727

[86] Bell RJ,Kreig A,Fouse SD.Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer..Science2015;348:1036-9 PMCID:PMC4456397

[87] Liu X,Shan Y,Liu D.Highly prevalent TERT promoter mutations in aggressive thyroid cancers..Endocr Relat Cancer2013;20:603-10 PMCID:PMC3782569

[88] Xing M,Liu X,Zhu G.BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence..J Clin Oncol2014;32:2718-26 PMCID:PMC4145183

[89] Macerola E,Giannini R,Giordano M.Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness..Virchows Arch2015;467:177-84

[90] Liu R,Zhu G,Ladenson PW.Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality..JAMA Oncol2016;

[91] Liu R.TERT promoter mutations in thyroid cancer..Endocr Relat Cancer2016;23:R143-55 PMCID:PMC4750651

[92] Nagore E,Rachakonda S,Requena C.TERT promoter mutations in melanoma survival..Int J Cancer2016;139:75-84

[93] Liu R,Zhu G.Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer..Nat Commun2018;9:579 PMCID:PMC5805723

[94] Pilati C,Nault JC,Boulai A.Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation..Cancer Cell2014;25:428-41

[95] Ko E,Jung ES,Jung G.The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer..Oncotarget2016;7:684-99 PMCID:PMC4808026

[96] Ding D,Zhou J,Cong YS.Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-kappaB-dependent transcription..FASEB J2013;27:4375-83

[97] Park JI,Hong JY,Jun S.Telomerase modulates Wnt signalling by association with target gene chromatin..Nature2009;460:66-72 PMCID:PMC4349391

[98] Kiyono T,Koop JI,Galloway DA.Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells..Nature1998;396:84-8

[99] Li X,Kang W,Wang M.Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features..Theranostics2018;8:1740-51 PMCID:PMC5858179

[100] Dhanasekaran R,Roberts LR.Genomic medicine and implications for hepatocellular carcinoma prevention and therapy..Gastroenterology2019;156:492-509 PMCID:PMC6340723

[101] Mizukoshi E,Kitahara M,Arai K.Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma..Cancer Lett2015;364:98-105

[102] Mizukoshi E,Arai K,Sakai A.Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma..Hepatology2011;53:1206-16